Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

PURPOSE: TH-302 is an investigational hypoxia-activated prodrug that releases the DNA alkylator bromo-isophosphoramide mustard in hypoxic settings. This phase II study (NCT01144455) evaluated gemcitabine plus TH-302 in patients with previously untreated, locally advanced or metastatic pancreatic can...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Borad, Mitesh J., Reddy, Shantan G., Bahary, Nathan, Uronis, Hope E., Sigal, Darren, Cohn, Allen L., Schelman, William R., Stephenson, Joe, Chiorean, E. Gabriela, Rosen, Peter J., Ulrich, Brian, Dragovich, Tomislav, Del Prete, Salvatore A., Rarick, Mark, Eng, Clarence, Kroll, Stew, Ryan, David P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2015
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4881365/
https://ncbi.nlm.nih.gov/pubmed/25512461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.55.7504
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados